Clinical features, treatment, and outcomes of anti-PD-1/PD-L1 immune checkpoint inhibitors induced dermatomyositis.

Key Points

• The aim is to assess the clinical features and treatment outcomes of dermatomyositis induced by anti-PD-1/PD-L1 therapy.
• Monitoring cutaneous and muscular symptoms in patients undergoing anti-PD-1/PD-L1 therapy.
• Implementing interventions based on the severity of symptoms in diagnosed dermatomyositis cases.
• Recommends early detection of dermatomyositis during treatment.
• Highlights the need for timely interventions according to symptom severity.

Abstract